SemaThera
Business Services · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1 Av Du Mont-Royal O Suite 800, Montreal...Website
www.semathera.comRevenue
<$5 MillionIndustry
About SemaThera
SemaThera Inc. is focused on developing innovative treatments for diabetic and other retinal degenerative diseases, addressing the significant impact of diabetes on vision. The company has conducted over a decade of research into the role of semaphorin 3A in diabetic retinopathy, leading to the creation of biological traps that sequester harmful proteins and cytokines. Their products aim to reduce retinal vascular leakage, inflammation, and promote re-vascularization in affected patients. SemaThera collaborates with leading organizations, including a partnership with Roche, to advance their therapeutic solutions.Explore more
SemaThera Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to SemaThera
Compare insights from companies similar to SemaThera, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
SemaThera Tech Stack
A closer look at the technologies used by SemaThera
Top Business Services Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding SemaThera
Sign Up For FreeTo access detailed company insights
SemaThera Inc. is focused on developing innovative treatments for diabetic and other retinal degenerative diseases, addressing the significant impact of diabetes on vision. The company has conducted over a decade of research into the role of semaphorin 3A in diabetic retinopathy, leading to the creation of biological traps that sequester harmful pr... Read More
